Triple-drug treatment clears HIV in newborn primates within days of exposure

For decades, HIV research has been defined by a frustrating asymmetry: antiretroviral therapy can suppress the virus to undetectable levels for a lifetime, but almost nothing can eliminate it once it has established itself in the body's cellular reservoirs. A new study in newborn nonhuman primates offers a rare exception, describing a one-time triple-drug regimen that appears to have cleared the virus entirely when given within three days of exposure.

The treatment combined three distinct tools: standard antiretroviral drugs, which block the virus from replicating; broadly neutralizing antibodies, which can bind to many different strains of HIV and mark infected cells for destruction; and an experimental antibody called leronlimab, which blocks a receptor the virus uses to enter human immune cells. Individually, none of the three approaches was sufficient to clear the infection in the animal model. Together, given as a single early intervention, they appeared to eliminate it.

The research addresses one of the most consequential unsolved problems in HIV medicine: mother-to-child transmission. Despite major advances in prevention, tens of thousands of infants are still born with HIV each year worldwide, disproportionately in regions with limited access to maternal antiretroviral therapy during pregnancy. For infants born with the virus, the current standard of care is lifelong antiretroviral treatment, beginning as early as possible after birth, which suppresses but does not eliminate the infection.

The study's authors focused on the newborn period specifically because a newly acquired infection has not yet had time to establish the deep, latent viral reservoirs that make HIV so difficult to cure in adults. In older children and adults, the virus inserts its genetic material into the DNA of long-lived immune cells, creating a hidden pool that can reactivate even after years of undetectable viral load. In a very young infant treated within days of exposure, researchers reasoned, that reservoir may not yet be fully formed — leaving a narrow but potentially exploitable window.

The result builds on a widely discussed 2013 case, sometimes called the "Mississippi baby," in which an infant treated with antiretrovirals very shortly after birth appeared to be free of detectable virus for more than two years before it unexpectedly resurfaced. That case demonstrated both the promise and the fragility of very early intervention, and helped motivate the search for a more robust combination that could close off the reservoir more completely than antiretrovirals alone.

The addition of broadly neutralizing antibodies is a comparatively recent development in HIV research, drawn from a subset of chronically infected people whose immune systems naturally produce antibodies capable of recognizing many different viral variants. Isolating and reproducing these antibodies has become a major research pathway, both for treatment and for vaccine design, because they can attack infected cells directly rather than merely blocking viral replication, as antiretrovirals do.

Leronlimab, the third component, works differently again: it blocks CCR5, a receptor on the surface of immune cells that HIV typically uses as a doorway to infect them. Blocking that doorway does not affect cells the virus has already infected, but it can slow the spread of infection to new cells during the critical early days after exposure, buying time for the other two components to act.

The researchers emphasized that the study was conducted in nonhuman primates, and that translating the approach to human infants will require substantial additional testing for safety, dosing and timing before any clinical application could be considered. Newborn immune systems and metabolisms differ meaningfully from those of adult humans, let alone other primate species, and interventions that work safely in a controlled animal study do not always translate cleanly to clinical use.

HIV researchers not involved in the study described the findings as an important proof of concept rather than an imminent cure, noting that the three-day treatment window is narrow and would require extremely rapid diagnosis and treatment initiation — a significant logistical challenge in regions where prenatal HIV testing and neonatal care infrastructure are limited. Even if the approach is eventually validated in humans, it would likely apply only to infants identified and treated within days of birth, not to people already living with established infections.

Still, for a field that has spent decades managing HIV as a permanently suppressible but incurable infection, a demonstrated case of full viral clearance — even in a narrow window, even in an animal model — represents a meaningful data point. Researchers say the next steps involve refining the antibody combinations, better understanding exactly how the reservoir failed to establish itself, and beginning the long process of safety testing that would be required before any trial in human newborns could be considered.